Form 144 notice for proposed sale of 10,000 common shares by an insider through Morgan Stanley Smith Barney LLC. The filing states the aggregate market value of the shares to be sold is $1,708,087.44 based on 10,000 shares, with approximately 19,596,560 shares outstanding for the issuer. The approximate date of sale is listed as 09/23/2025. The filer reports no securities sold in the past three months. Acquisition details show the 10,000 shares were acquired in multiple lots between 06/04/2022 and 06/06/2025 via restricted stock grants and exercised share transactions, with specific lot sizes and payment methods noted where applicable.
Form 144 notice for Ligand Pharmaceuticals, Inc. (LGNZZ): An insider filed to sell 10,000 shares of the company's common stock through Charles Schwab & Co., with an approximate aggregate market value of $1,685,000. The filing reports the shares were acquired in the open market on October 9, 2014 (payment dated October 1, 2014) and the proposed sale date is September 17, 2025 on NASDAQ. The filing states there were 19,596,560 shares outstanding, and no securities were sold by the filer in the past three months. The filer certifies no undisclosed material information is known.
Ligand Pharmaceuticals Incorporated reported that it entered into a Third Amendment to its existing credit agreement with Citibank and other lenders. The amendment extends the loan’s maturity date to September 12, 2028, giving the company more time before the debt comes due.
The amendment also tightens a key financial test. Ligand must maintain at least $55 million of consolidated EBITDA for the trailing four-quarter period ending September 30, 2025 and for each trailing four-quarter period after that. This sets a clear performance threshold the company needs to meet to stay in compliance with its credit facility.